Semaglutide Side Effects: What to Expect and How to Manage Them

Starting semaglutide for weight loss is exciting — but it’s normal to have questions about side effects before your first dose. Most people do experience some side effects, especially in the first few weeks or after a dose increase, and most of those side effects are mild, temporary, and manageable with a few simple adjustments. This guide covers every common semaglutide side effect backed by real clinical trial data, the serious side effects that need immediate medical attention, how this data applies if you’re using a compounded formulation, what the FDA has and hasn’t found regarding mental health risk, and practical ways to feel better while your body adjusts.

Key Takeaways

• The most common semaglutide side effects are gastrointestinal: nausea (44%), diarrhea (30%), vomiting (24%), and constipation (24%), based on clinical trial data compared with placebo.
• Side effects are usually strongest in the first few weeks of treatment and after each dose increase, then ease as your body adjusts.
• Most side effects can be significantly reduced with eating strategies — smaller meals, less fat, slower eating, and staying upright after meals.
• Serious but rare side effects include pancreatitis, gallbladder problems, and a boxed warning about thyroid C-cell tumors seen in animal studies.
• These percentages come from trials of Wegovy, the FDA-approved brand; see the compounded-medication section below for how that applies to your specific prescription.
• Contact your provider immediately for severe abdominal pain, vomiting you can’t keep fluids down through, signs of an allergic reaction, or a lump/swelling in your neck.

How Common Are Semaglutide Side Effects? The Real Numbers

Side effect rates vary depending on the source, and a lot of what’s published online rounds numbers loosely. Here’s what semaglutide’s FDA-approved prescribing information actually reports from clinical trials, compared with placebo:

The takeaway: gastrointestinal side effects are genuinely common, not rare exceptions — but they’re also the ones most responsive to simple diet and pacing adjustments, which is why most patients are able to stay on treatment through them. These figures match the independently reviewed rates published by Drugs.com’s clinical pharmacist team, for anyone who wants a second source.

When Do Semaglutide Side Effects Start — and How Long Do They Last?

Semaglutide is started at a low dose and increased roughly every four weeks, which is intentional: it gives your digestive system time to adjust before the next increase. Because of that schedule, side effects tend to follow a predictable pattern:

• First 1-2 weeks on a new dose: side effects are usually at their most noticeable.
• Weeks 3-4: most people notice gradual improvement as the body adapts.
• After a dose increase: mild side effects, especially nausea, can temporarily return before settling again.
• Full adjustment: for most people, digestive side effects meaningfully improve within a few weeks, though it can take two to three months for the body to fully adjust across dose increases. This tracks with a clinical study on GI tolerability of once-weekly semaglutide, which found symptoms clustered around dose-escalation periods and eased between them.

If a side effect is getting worse instead of better over time — rather than following this improve-then-reset pattern with each dose change — that’s a good reason to check in with your provider rather than assume it will pass on its own.

Common Semaglutide Side Effects and How to Manage Them

Nausea and Vomiting

Nausea is the single most common semaglutide side effect, affecting 44% of patients in clinical trials, with vomiting affecting 24%. Semaglutide slows how quickly food leaves your stomach and acts on appetite-and-nausea centers in the brain — which is part of how it helps you eat less, but it’s also why nausea shows up early.

What helps:

• Eat smaller, more frequent meals instead of three large ones
• Avoid greasy, fried, or high-fat foods, which digest slowly and worsen nausea
• Eat slowly and stop at the first sign of fullness
• Stay upright for 2-3 hours after eating
• Try ginger tea, ginger chews, or peppermint
• Some patients find taking their dose in the evening helps them sleep through the worst of it

Contact your provider if vomiting is severe, persistent, or keeping you from holding down fluids — this can lead to dehydration and needs medical attention.

Diarrhea

Diarrhea affects about 30% of patients on semaglutide, nearly double the placebo rate. It happens because your digestive system is adjusting to slower, altered motility.

What helps:

• Stay well hydrated
• Avoid trigger foods like dairy, beans, and high-fat meals
• Skip alcohol, which irritates the digestive tract
• Add fiber gradually rather than all at once
• Avoid sugar-alcohol sweeteners (sorbitol, mannitol, xylitol) common in “sugar-free” products, which can worsen diarrhea
• Track your food for a week or two to spot personal triggers

Constipation

Constipation affects roughly 24% of patients — and some people cycle between diarrhea and constipation as their digestive system adjusts, since semaglutide slows transit through the entire GI tract, not just the stomach.

What helps:

• Drink at least 8 glasses of water a day
• Increase fiber gradually through fruits, vegetables, and whole grains
• Take a short walk after meals
• Keep a consistent bathroom routine
• Ask your provider before starting a stool softener or laxative

Stomach Pain and Abdominal Discomfort

About 20% of patients report abdominal pain, ranging from mild cramping to more noticeable discomfort after eating, as food sits in the stomach longer than usual.

What helps:

• Eat slowly and put your fork down between bites
• Stop when satisfied, not full — appetite signals change on semaglutide
• Avoid spicy, fatty, or acidic trigger foods
• Don’t lie down right after eating
• A heating pad can ease mild cramping

Severe abdominal pain — especially pain that radiates to your back — is not a “normal” side effect to push through. It can be an early sign of pancreatitis or gallbladder problems (below) and should be evaluated promptly.

Headache

Reported by about 14% of patients, headaches tend to be more common early in treatment and often ease as the body adjusts. Our tirzepatide headache guide covers the same dehydration, blood-sugar, and caffeine-related mechanisms in more depth if you want the full picture — the causes are largely the same across GLP-1 medications.

What helps: stay hydrated, eat regular meals to avoid blood sugar dips, rest in a quiet dark room if needed, and check with your provider before taking over-the-counter pain relievers.

Fatigue

About 11% of patients report fatigue, often tied to eating less, shifts in blood sugar, or mild dehydration from GI side effects.

What helps: prioritize 7-9 hours of sleep — sleep and stress affect weight loss more than most people realize — don’t cut calories too aggressively while adjusting to the medication, eat enough protein to protect lean muscle, and add gentle movement like walking, which tends to boost energy more than rest alone.

Dizziness, Gas, Indigestion, and Burping

These affect a smaller share of patients (roughly 6-9% each) but are worth knowing about. Dizziness is more likely if you’re dehydrated or, for patients with type 2 diabetes on insulin or sulfonylureas, if blood sugar drops too low. Gas, indigestion, and burping usually respond to the same eating pace and portion strategies that help with nausea.

Injection Site and Skin Reactions

Some patients notice mild redness, itching, or bruising at the injection site. Rotating injection sites (stomach, thigh, or upper arm) and letting the medication reach room temperature before injecting can reduce this — see our full guide to semaglutide injections, technique, and what to expect for a step-by-step walkthrough.

Serious Semaglutide Side Effects to Know About

These are far less common than the digestive side effects above, but they’re the ones that warrant immediate medical attention rather than home management.

Thyroid C-cell tumors (boxed warning). In animal studies, semaglutide caused thyroid C-cell tumors, including medullary thyroid carcinoma. It’s not known whether this occurs in humans, but out of caution, semaglutide should not be used by anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Because of this warning, semaglutide-containing products are dispensed with an FDA-required Medication Guide, and you should receive and read it with every prescription. Contact your provider promptly if you notice a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath.

Pancreatitis. Rare but serious. Watch for severe abdominal pain (especially pain radiating to the back), persistent nausea or vomiting, and fever — stop the medication and seek care right away if these occur. If you or your provider decide to pause or discontinue treatment for any reason, read what happens if you stop taking semaglutide or tirzepatide first.

Gallbladder problems. Gallstones occur in roughly 2-3% of patients, more often during periods of rapid weight loss. Warning signs include severe upper abdominal pain, pain between the shoulder blades, fever, and yellowing of the skin or eyes.

Kidney problems. Dehydration from vomiting or diarrhea can strain the kidneys. Staying hydrated during any GI side effects is one of the simplest ways to protect against this.

Low blood sugar (hypoglycemia). Mainly a risk for patients with type 2 diabetes who also take insulin or a sulfonylurea — semaglutide alone rarely causes dangerously low blood sugar in people without diabetes.

Allergic reactions. Rare, but seek emergency care immediately for facial or throat swelling, difficulty breathing, or a severe rash.

Vision changes. Rapid blood sugar improvement can temporarily worsen diabetic retinopathy in some patients with type 2 diabetes. Report any new blurry vision, floaters, or vision loss to your provider.

What About Mental Health? What the FDA Actually Found

This is worth addressing directly, especially because semaglutide specifically has been part of this conversation since it started. Beginning in 2023, the FDA evaluated post-market reports of suicidal thoughts or actions in patients taking GLP-1 receptor agonists, including semaglutide. In January 2024, the FDA’s preliminary review found no evidence supporting a causal link between these medications and suicidal thoughts or behavior. A subsequent meta-analysis of 91 placebo-controlled trials involving more than 107,000 patients, plus a separate real-world cohort study of over 2.2 million patients through FDA’s Sentinel surveillance system, found no increased risk of suicidal ideation or behavior.

Based on that evidence, in January 2026 the FDA formally requested that manufacturers remove the suicidal ideation and behavior warning entirely from the labeling of Wegovy, Zepbound, and Saxenda (FDA Drug Safety Communication) — Wegovy being the FDA-approved brand version of semaglutide for weight management. This is a rare and notable example of the FDA’s postmarket surveillance system working in the other direction, removing a precautionary warning once the evidence didn’t support it rather than just adding new ones. If you or someone you know is having thoughts of self-harm, that’s still worth talking to a provider about directly — this finding is about causation from the medication specifically, not a statement that mental health concerns don’t deserve attention.

Does This Data Apply to Compounded Semaglutide Too?

This is worth making explicit rather than assuming readers already know it. The percentages and safety data throughout this article come from clinical trials of Wegovy, the FDA-approved brand-name semaglutide product. Medica Weight Loss, like many telehealth weight-loss providers, offers compounded semaglutide — prepared by a licensed compounding pharmacy rather than manufactured by Novo Nordisk. Compounded semaglutide that uses the same active pharmaceutical ingredient works through the same mechanism, but it is not independently evaluated by the FDA for safety, effectiveness, or quality the way Wegovy is, and the general side-effect profile above should reasonably apply to it for that reason — GI symptoms, the thyroid boxed warning, and dose-related patterns are driven by the active ingredient itself, not the brand name on the box.

Two things are worth knowing specifically about compounded semaglutide, beyond what applies to compounded GLP-1s generally (our prescription weight-loss medication safety guide covers the broader 503A regulatory framework, USP compounding standards, and quality-control track record in full):

The regulatory landscape recently changed. For several years, compounding pharmacies could prepare semaglutide at scale under an FDA exception that applies when an FDA-approved drug is in official shortage. That shortage was declared resolved in February 2025, and the compliance window for compounders to wind down under the old exception closed in mid-2025. Compounded semaglutide is still legally available today, but only under narrower circumstances — most commonly when a licensed provider documents a specific clinical reason for an individual patient, such as a strength or dosage form that isn’t commercially available, or an allergy to an inactive ingredient in the approved product. It’s a reasonable question to ask your provider how your specific prescription is classified.

Not all compounded semaglutide is the same active ingredient. The FDA has specifically warned that some compounders have substituted semaglutide salt forms — semaglutide sodium or semaglutide acetate — in place of the base semaglutide used in FDA-approved products (FDA: Concerns with Unapproved GLP-1 Drugs). The FDA has stated it’s not aware of a basis for treating these salt forms as equivalent to approved semaglutide, since they haven’t been shown to share the same safety and effectiveness profile. This is a good question to ask any compounding pharmacy directly: is the active ingredient base semaglutide, and how is potency verified?

None of this means compounded semaglutide is unsafe — it means understanding your specific formulation and its sourcing is part of using it safely, the same way you’d want to know the source of any prescription medication.

How the FDA Monitors Safety After Approval

FDA approval isn’t the end of safety monitoring. After a drug reaches the market, the FDA continues tracking real-world outcomes through its Adverse Event Reporting System (FAERS), and labels get updated, sometimes years later, as new information emerges — the suicidal-ideation warning removal described above is a direct example. You can participate in this system directly: if you experience a side effect you believe is related to semaglutide, you can report it yourself through the FDA’s MedWatch program at fda.gov/medwatch, in addition to notifying your provider.

When to Call Your Doctor

Reach out to your healthcare provider right away if you experience:

• Severe abdominal pain, especially pain that spreads to your back
• Vomiting that won’t stop or that prevents you from keeping fluids down
• Yellowing of the skin or eyes
• Signs of a serious allergic reaction (facial/throat swelling, trouble breathing)
• A lump or swelling in your neck, or a hoarse voice that doesn’t go away
• Decreased urination, confusion, or other signs of dehydration
• New vision changes

Who Should Be Cautious With Semaglutide

Semaglutide isn’t right for everyone. According to Mayo Clinic’s clinical reference on semaglutide, it’s contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2, and it should be used cautiously — with close monitoring — by people with a history of pancreatitis, gallbladder disease, or severe gastroparesis. If you’re weighing semaglutide against tirzepatide or want a side-by-side comparison of both, see our semaglutide vs. tirzepatide guide. This is exactly why medical screening before starting treatment matters, rather than starting a GLP-1 medication without provider oversight.

How Medica Weight Loss Supports You Through Side Effects

Every patient starting semaglutide treatment through Medica Weight Loss goes through in-house medical screening first, so your provider can flag any personal risk factors before you begin. Your dose is increased gradually on a proven schedule to minimize side effects, and our team is available to help you adjust your approach — food choices, timing, hydration — if side effects show up along the way. New to the program? Start with our step-by-step guide to beginning your weight loss journey with Medica, and once side effects settle in, our guide on how to maximize your results with semaglutide covers what comes next.

Frequently Asked Questions

What is the most common side effect of semaglutide? Nausea is the most common, affecting about 44% of patients in clinical trials, most often in the first few weeks of treatment or after a dose increase.

How long do semaglutide side effects last? Most digestive side effects improve within a few weeks as your body adjusts, though it can take two to three months to fully adjust across all your dose increases. Side effects often temporarily return, more mildly, each time your dose goes up. (For a related question — how long semaglutide itself stays in your system after your last dose — see our full timeline breakdown.)

Do side effects get worse with every dose increase? They can flare up briefly after each increase, but for most patients they’re less intense than the first time and settle again within a couple of weeks.

Can I avoid semaglutide side effects completely? Not entirely — most patients experience at least mild GI symptoms — but eating smaller meals, avoiding high-fat foods, and following the standard gradual dose-escalation schedule significantly reduces their severity for most people.

What’s the most serious semaglutide side effect? Pancreatitis and gallbladder problems are the serious side effects most likely to require urgent care, though both are uncommon. The boxed warning for thyroid C-cell tumors is based on animal studies; its relevance to humans hasn’t been confirmed.

Is semaglutide safe if I don’t have diabetes? Yes — semaglutide is FDA-approved for chronic weight management independent of a diabetes diagnosis, and hypoglycemia (low blood sugar) is not a meaningful risk unless you’re also taking insulin or a sulfonylurea.

Does this side-effect data apply if I’m using compounded semaglutide rather than Wegovy? The general pattern should reasonably apply, since it’s the same active ingredient and mechanism, but the data itself comes from trials of the FDA-approved brand product — compounded formulations aren’t independently tested by the FDA. See the compounded-semaglutide section above for the full explanation.

Does semaglutide cause depression or suicidal thoughts? The FDA’s review found no evidence of a causal link, and in 2026 requested this warning be removed from Wegovy’s labeling (along with Zepbound and Saxenda) entirely. If you’re experiencing new or worsening mental health symptoms for any reason, that’s still worth discussing with your provider.

How do I report a side effect to the FDA myself? Through the FDA’s MedWatch program at fda.gov/medwatch, in addition to telling your provider.

When should I call my doctor instead of managing a side effect at home? Any time a symptom is severe, doesn’t improve, or matches one of the serious-side-effect warning signs above — especially severe abdominal pain, vomiting you can’t keep fluids down through, or signs of an allergic reaction.

The Bottom Line

Semaglutide side effects are common but usually manageable, especially with the right eating strategies and a gradual dose schedule. Knowing what’s normal, what’s temporary, and what actually needs urgent attention lets you go into treatment prepared rather than anxious — and knowing how this data applies to your specific prescription, especially if you’re using a compounded formulation, is part of that preparation. If you’re considering semaglutide for weight loss, a medical screening with a licensed provider is the best way to understand how your own health history factors in. For broader questions about pricing, delivery, or eligibility, see our full FAQ on Medica Weight Loss programs.

This article is for educational purposes only and is not a substitute for professional medical advice. Talk to your healthcare provider about your individual risk factors before starting or stopping any medication.

Sources

• Wegovy (semaglutide) FDA Prescribing Information
• Wegovy Side Effects and How to Manage Them — Drugs.com
• Wharton, S. et al. (2021), “Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg,” Diabetes, Obesity and Metabolism
• Mayo Clinic — Semaglutide (subcutaneous route)
• FDA: Requests removal of suicidal behavior and ideation warning from GLP-1 RA medications
• FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
• FDA: MedWatch Safety Information and Adverse Event Reporting Program

Take action

Transform Your Journey: Science-Backed Weight Loss!

Revolutionary medication, lasting weight results

• No insurance required
• No hidden fees, no recurring charges
• Medically supervised
• Free shipping